Antriabio Inc (ANTB) 1.9700 $ANTB AntriaBio names David

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 2:09 PM

Antriabio Inc (ANTB) 1.9700 $ANTB

AntriaBio names David F. Welch PhD to board
M2 - Tue Jun 30, 5:46AM CDT
AntriaBio Inc (OTC:ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced on Monday that it has appointed David F. Welch, PhD to the company's board of directors.
INFN: 20.21 (+0.51)

AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
Marketwired - Mon Jun 29, 7:01AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"

(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today the appointment of David F. Welch, Ph.D., President and Co-Founder of Infinera Corporation (NASDAQ: INFN), to the Company's Board of Directors. Dr. Welch joins AntriaBio's Board as the Company prepares to conduct clinical studies for its lead product candidate, AB101, a potential once-weekly basal insulin in development for patients with type 1 and type 2 diabetes.
INFN: 20.21 (+0.51)

Preclinical Data At ADA Supports Development Of AntriaBio's AB101
Jason Napodano, CFA - at Seeking Alpha - Thu Jun 11, 8:55AM CDT

AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
Marketwired - Mon Jun 08, 6:30AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"

(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, released preclinical results for its lead product candidate, AB101, at the American Diabetes Association 75th Scientific SessionsÂ® in Boston. The results demonstrated that AB101 has comparable in vitro pharmacology to native insulin, and in two animal species exhibited a prolonged subcutaneous insulin absorption profile, resulting in slow onset, peakless and sustained insulin levels with corresponding glucose reductions, without acute hypoglycemia caused by an insulin burst. These observations occurred at clinically relevant dose projections, demonstrating proof of concept of the potential for AB101 as a weekly subcutaneous basal insulin therapy in patients with diabetes mellitus.

IPOs & Transactions Week in Review: May 18 - 22 plus "How-to" M&A Webinar Videos
PR Newswire - Tue May 26, 11:20AM CDT
Vintage, the capital markets, corporate services and institutional & fund services division of PR Newswire, has released its weekly IPO and Transaction summary.

AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Marketwired - Mon May 11, 7:02AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"

(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it will be presenting data for its lead product candidate, AB101, on Saturday, June 6, 2015 at the American Diabetes Association 75th Scientific SessionsÂ® in Boston. The abstract, accepted for oral presentation, will include results from preclinical in vitro and in vivo pharmacology studies of AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes.

AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Marketwired - Thu Jan 08, 6:35AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"

(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board.

AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Marketwired - Wed Jan 07, 7:02AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"

(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment.

AntriaBio Announces $7 Million Private Placement
Marketwired - Mon Jan 05, 6:35AM CST
AntriaBio, Inc. ("Company"

(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7 million in a private placement transaction. At $1.85 per unit, institutions and accredited investors were issued one share of common stock and one warrant exercisable for three years at $2.50 for one share of common stock. Notably, the Company was successful in raising over $18 million through equity financings in 2014.

AntriaBio Extinguishes $44 Million Contingent Liability
Marketwired - Mon Nov 10, 7:06AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully extinguished $44 million of contingent milestone payments owed by AntriaBio to the bankruptcy estate of PR Pharmaceuticals, Inc. (the "Estate"

.

AntriaBio, Inc. - "Big Pharma Strategic Partnerships"
ACCESSWIRE - Wed Aug 20, 9:10AM CDT
New York, NY / ACCESSWIRE / August 20, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

AntriaBio, Inc. - "Expanding the Treatment Options"
ACCESSWIRE - Mon Aug 04, 8:41AM CDT
New York, NY / August 4, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's VP of Clinical Development, Dr. Brian Roberts. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
Marketwire - Wed Jul 23, 6:35AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced today the appointment of Barry Sherman, M.D. to its Board of Directors.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

tm:rw Revolutionizes Retail with Live TikTok Studios

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

Arrvel's Thermal Printers: Aiming at E-Com Sellers

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...

AI in Music: CITY JAM Focuses on Human Creativity

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...

New Docs Spotlight Psychiatry on World Mental Health Day

Unmasking Mental Health on the Global Stage Hold onto your hats, folks. The Scientology Network is cranking up the heat this World Mental Health Day. On October 10, they’re rolling out a program that puts the spotlight on CCHR’s crusade against what they see as dark forces in the psychiatric industry. It’s a marathon of documentaries that dives into allegations of...

Young Visionaries Win Junior Medals at STARMUS VIII

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

Emdoor’s Rugged Devices Fuel Industry Growth Globally

Emdoor Information: A Sturdy Path in Rugged Computing Dive into the heart of the rugged computing terrain, and you may very well run into Emdoor Information—an 18-year-old titan from Shenzhen that’s carved its niche on the backs of rugged tablets, laptops, and handhelds. Publicly listed since 2023 on China’s A-share main board, Emdoor isn't just any player in this...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...